title: Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma.
authors.forename: P
authors.initials: P
authors.lastname: Moreau
authors.forename: F
authors.initials: F
authors.lastname: Cavallo
authors.forename: X
authors.initials: X
authors.lastname: Leleu
authors.forename: C
authors.initials: C
authors.lastname: Hulin
authors.forename: M
authors.initials: M
authors.lastname: Amiot
authors.forename: G
authors.initials: G
authors.lastname: Descamps
authors.forename: T
authors.initials: T
authors.lastname: Facon
authors.forename: M
authors.initials: M
authors.lastname: Boccadoro
authors.forename: D
authors.initials: D
authors.lastname: Mignard
authors.forename: J L
authors.initials: JL
authors.lastname: Harousseau
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001897:Boronic Acids / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000069286:Bortezomib; D019008:Drug Resistance, Neoplasm; D004359:Drug Therapy, Combination; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D011719:Pyrazines / Q000493:pharmacokinetics / Q000627:therapeutic use*; D017526:Receptor, IGF Type 1 / Q000276:immunology*; D015996:Survival Rate; D014018:Tissue Distribution; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib; D017526:Receptor, IGF Type 1; C545477:AVE1642